Microdosing involves the off-label use of GLP-1 medications (semaglutide and tirzepatide) at much smaller doses than the standard recommended dose, such as: Consuming a fraction of a starter dose, such as 0.05 mg of Ozempic instead of 0.25 mg
A phase II trial focusing on individuals with overweight or obesity, coupled with hypertension or dyslipidemia but without T2D, found that cagrilintide (2.4 mg) alongside diet and exercise, led to a 10% body weight reduction compared to 3% with placebo over 26 weeks [99]
GLP-1 agonists (and dual agonists) don't cause significantly more muscle loss than calorie restriction alone
On the contrary, studies in animal models of IBD suggest that the use of DPP-IV inhibitors decreases disease activity
Session 6 Back Line & Sacrum Works from the soles of the feet up the back fascia, sacrum, and into the spine